Company: VCYT
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001384101-25-000110
Chunk: 95

Company: VERACYTE, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 95
---
 3,763 137%11,042 5,503 5,539 101%Income (loss) before income taxes1,250 7,361 (6,111)(83)%8,678 5,453 3,225 59%Income tax provision2,230 1,627 603 37%2,611 1,583 1,028 65%Net income (loss)$(980)$5,734 $(6,714)(117)%$6,067 $3,870 $2,197 57%Other Operating Data:    Diagnostic tests reported42,441 36,057 6,384 18%80,519 67,026 13,493 20%Product tests sold2,525 2,966 (441)(15)%5,102 5,421 (319)(6)%Total test volume44,966 39,023 5,943 15%85,621 72,447 13,174 18%Depreciation and amortization expense$5,489 $5,738 $(249)(4)%$10,851 $11,328 $(477)(4)%Stock-based compensation expense$10,985 $9,854 $1,131 11%$21,943 $17,873 $4,070 23%

Revenue

Revenue increased $15.7 million for the three months ended June 30, 2025 compared to the same period in 2024. This was primarily due to a $15.3 million increase in testing revenue and a $0.8 million increase in our biopharmaceutical and other revenue, partially offset by a $0.3 million decrease in our product revenue. The 14% growth in testing revenue was primarily driven by an 18% volume increase, partially offset by lower prior period collections compared to the prior year period. 

Revenue increased $33.4 million for the six months ended June 30, 2025 compared to the same period in 2024. This was primarily due to a $32.3 million increase in testing revenue and a $1.3 million increase in our biopharmaceutical and other revenue, partially offset by a $0.3 million decrease in our product revenue. The 16% growth in testing revenue was primarily driven by a 20% volume increase, partially